Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.K. López, R. Saracho, L.F. García, M.A. Gentil, P. Castro, J. Castilla, et al.
Informe de diálisis y trasplante año 2001 de la Sociedad Española de Nefrología y Registros Autonómicos.
Nefrología, 24 (2004), pp. 21-33
[2.]
P. Rossing.
Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.
Diabetologia, 49 (2006), pp. 11-19
[3.]
American Diabetes Association.
Standards of Medical Care in Diabetes-2006.
Diabetes Care, 29 (2006), pp. S4-S42
[4.]
C.I. Johnston.
Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control.
J Hypertens Suppl, 10 (1992), pp. S13-S26
[5.]
C.E. Mogensen.
Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy.
Br Med J (Clin Res Ed), 285 (1982), pp. 685-688
[6.]
H.H. Parving, P. Jacobsen, K. Rossing, U.M. Smidt, E. Hommel, P. Rossing.
Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy.
Kidney Int, 49 (1996), pp. 1778-1782
[7.]
V.J. Dzau, R. Re.
Tissue angiotensin system in cardiovascular medicine. A paradigm shift?.
Circulation, 89 (1994), pp. 493-498
[8.]
M.R. Weir, V.J. Dzau.
The renin-angiotensin-aldosterone system: a specific target for hypertension management.
Am J Hypertens, 12 (1999), pp. S205-S213
[9.]
E. Balcells, Q.C. Meng, W.H. Johnson Jr, S. Oparil, L.J. Dell’Italia.
Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations.
Am J Physiol, 273 (1997), pp. H1769-H1774
[10.]
M. Ihara, H. Urata, A. Kinoshita, J. Suzumiya, M. Sasaguri, M. Kikuchi, et al.
Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta.
Hypertension, 33 (1999), pp. 1399-1405
[11.]
X.R. Huang, W.Y. Chen, L.D. Truong, H.Y. Lan.
Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease.
J Am Soc Nephrol, 14 (2003), pp. 1738-1747
[12.]
M.E. Rosenberg, L.J. Smith, R. Correa-Rotter, T.H. Hostetter.
The paradox of the renin-angiotensin system in chronic renal disease.
Kidney Int, 45 (1994), pp. 403-410
[13.]
N.K. Hollenberg.
Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition.
J Am Soc Nephrol, 10 (1999), pp. S239-S242
[14.]
Z. Cao, D.J. Kelly, A. Cox, D. Casley, J.M. Forbes, P. Martinello, et al.
Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis.
Kidney Int, 58 (2000), pp. 2437-2451
[15.]
G. Wolf.
Angiotensin II as a mediator of tubulointerstitial injury.
Nephrol Dial Transplant, 15 (2000), pp. 61-63
[16.]
Z. Cao, F. Bonnet, B. Davis, T.J. Allen, M.E. Cooper.
Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats.
Clin Sci (Lond), 100 (2001), pp. 591-599
[17.]
C. Zoja, D. Corna, D. Camozzi, D. Cattaneo, D. Rottoli, C. Batani, et al.
How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach.
J Am Soc Nephrol, 13 (2002), pp. 2898-2908
[18.]
P. Jacobsen, S. Andersen, K. Rossing, B.V. Hansen, H.H. Parving.
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
Nephrol Dial Transplant, 17 (2002), pp. 1019-1024
[19.]
P. Jacobsen, S. Andersen, K. Rossing, B.R. Jensen, H.H. Parving.
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Kidney Int, 63 (2003), pp. 1874-1880
[20.]
P. Jacobsen, S. Andersen, B.R. Jensen, H.H. Parving.
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
J Am Soc Nephrol, 14 (2003), pp. 992-999
[21.]
C.E. Mogensen, S. Neldam, I. Tikkanen, S. Oren, R. Viskoper, R.W. Watts, et al.
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.
BMJ, 321 (2000), pp. 1440-1444
[22.]
A.M. Sengul, Y. Altuntas, A. Kurklu, L. Aydin.
Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.
Diabetes Res Clin Pract, 71 (2006), pp. 210-219
[23.]
N.H. Andersen, P.L. Poulsen, S.T. Knudsen, S.H. Poulsen, H. Eiskjaer, K.W. Hansen, et al.
Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.
Diabetes Care, 28 (2005), pp. 273-277
[24.]
K. Rossing, P.K. Christensen, B.R. Jensen, H.H. Parving.
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
Diabetes Care, 25 (2002), pp. 95-100
[25.]
K. Rossing, P. Jacobsen, L. Pietraszek, H.H. Parving.
Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Diabetes Care, 26 (2003), pp. 2268-2274
[26.]
R. Agarwal.
Add-on angiotensin receptor blockade with maximized ACE inhibition.
Kidney Int, 59 (2001), pp. 2282-2289
[27.]
R. Agarwal, S. Siva, S.R. Dunn, K. Sharma.
Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Am J Kidney Dis, 39 (2002), pp. 486-492
[28.]
J.H. Song, S.W. Lee, J.H. Suh, E.S. Kim, S.B. Hong, K.A. Kim, et al.
The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Clin Nephrol, 60 (2003), pp. 318-326
[29.]
N.B. Tutuncu, A. Gurlek, O. Gedik.
Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study.
Acta Diabetol, 38 (2001), pp. 157-161
[30.]
N. Nakao, G. Kimura.
Submaximal dose of trandolapril in the COOPERATE trial?.
Kidney Int, 64 (2003), pp. 1921-1922
[31.]
S. Yusuf.
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
Am J Cardiol, 89 (2002), pp. A18-25
Copyright © 2006. Sociedad Española de Endocrinología y Nutrición
